Journal of Clinical Investigation

March 28, 2024

Study identifies molecule as potential target for treating AML

While immune checkpoint inhibitors that target the PD-1 molecule on T-cells have proven to be effective with many cancers, these immunotherapies have not worked for acute myeloid leukemia (AML), but new research has identified a “cousin” molecule as a potential therapeutic target for AML. 

By Tom Wilemon
(iStock image)
March 25, 2024

VUMC team finds potential treatment for kidney fibrosis

By Bill Snyder
January 4, 2024

Potential AML therapy induces leukemic stem cell death

Vanderbilt researchers are studying a potential therapy for acute myeloid leukemia that targets the residual leukemic stem cells in bone marrow after treatment that are responsible for relapses and drug resistance.

By Tom Wilemon
From left, Sheila Collins, PhD, Ryan Ceddia, PhD, and Heidi Hamm, PhD, and their colleagues have identified a potential new approach to reducing the global impact of obesity and diabetes. (photo by Erin O. Smith)
September 6, 2023

Releasing a brake that drives obesity and diabetes

Vanderbilt researchers have uncovered a potential new way to help curb the rapidly rising worldwide prevalence of metabolic disorders, including obesity and diabetes.

By Bill Snyder
June 29, 2023

Selenium signal found in colorectal cancer: study

An antioxidant transporter of the trace mineral selenium that protects against inflammatory bowel disease has the opposite effect in colorectal cancer, where it promotes tumor growth, researchers at Vanderbilt University Medical Center have reported.

By Bill Snyder
Craig Brooks, PhD, and colleagues are studying a molecular mechanism that promotes chronic kidney disease following kidney injury. (photo by Erin O. Smith)
December 15, 2022

Novel therapeutic target identified for chronic kidney disease

Vanderbilt investigators have discovered a molecular mechanism that promotes chronic kidney disease following kidney injury.

By Leigh MacMillan
May 12, 2022

Study sheds light on the dark side of obesity

Vanderbilt research that promotes the anti-inflammatory pathway in macrophages could also reduce some of the bad side effects of obesity.
By Bill Snyder
April 7, 2022

New prognosis predictor and target for gastric cancer

The protein CGA — a subunit of glycoprotein hormones — is a biomarker that predicts chemoresistance in gastric cancer and could be targeted along with EGFR to restore chemosensitivity.
By Sarah E. Glass
July 8, 2021

Nature’s “recycler” could reduce heart disease risk: study

Researchers at Vanderbilt University Medical Center have identified potential new targets for the prevention of atherosclerosis through the enhancement of autophagy, a natural process for recycling damaged cellular material.
By Bill Snyder
April 1, 2021

Breast cancer cells ‘steal’ nutrients from immune cells: study

Triple-negative breast cancer cells engage in a “glutamine steal” — outcompeting T cells for the nutrient glutamine and impairing their ability to kill tumor cells, Vanderbilt researchers have discovered.
By Leigh MacMillan
March 25, 2021

Team studies new use for pulmonary hypertension drug

An FDA-approved medication enhances the function of T regulatory cells (Treg), a class of immune cells that restrains the immune response, Vanderbilt investigators have discovered.
By Leigh MacMillan
November 18, 2020

Why does COVID-19 seem to spare children? Vanderbilt University Medical Center study offers an answer 

Researchers at Vanderbilt University Medical Center (VUMC) and their colleagues have determined a key factor as to why COVID-19 appears to infect and sicken adults and older people preferentially while seeming to spare younger children. 
By Bill Snyder
February 20, 2020

Post-transplant diabetes may be reversible: study

Post-transplantation diabetes mellitus (PTDM), a common complication of immunosuppressive drugs that are given to prevent transplant rejection, may be reversible and at least partially preventable, researchers at VUMC report.
By Bill Snyder
1 2 3 4